Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C125603
http://purl.obolibrary.org/obo/NCIT_C125603
|
|---|---|
| Preferred Name | Bcl-2 Inhibitor BCL201 |
| Definitions |
A selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon administration, Bcl-2 inhibitor BCL201 binds to and inhibits the activity of Bcl-2. This restores apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in many cancers and plays an important role in the negative regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon administration, Bcl-2 inhibitor BCL201 binds to and inhibits the activity of Bcl-2. This restores apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in many cancers and plays an important role in the negative regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival. |
|---|---|
| label | Bcl-2 Inhibitor BCL201
|
| prefLabel | Bcl-2 Inhibitor BCL201
|
| in_subset |
See more
See less
|
| Preferred_Name | Bcl-2 Inhibitor BCL201
|
| Is_Value_For_GDC_Property | |
| Display_Name | Bcl-2 Inhibitor BCL201
|
| Maps_To | Bcl-2 Inhibitor BCL201
|
| PDQ_Open_Trial_Search_ID | 778922
|
| Has_Target | |
| FDA_UNII_Code | W93257I68I
|
| prefixIRI | NCIT:C125603
|
| NCI_Drug_Dictionary_ID | 778922
|
| Contributing_Source |
CTRP
FDA
|
| subClassOf | |
| code | C125603
|
| type | |
| PDQ_Closed_Trial_Search_ID | 778922
|
| Semantic_Type | Pharmacologic Substance
|
| CAS_Registry | 1448584-12-0
|
| NCI_META_CUI | CL504308
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |